Sutro Biopharma, Inc. (S09.F)

3,9000 -0,1800 (-4,41%) Börsenschluss: 03:29PM CEST

Sutro Biopharma, Inc.

111 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 881 6500
https://www.sutrobio.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 302

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. William J. Newell J.D.	CEO & Director	985,37k	N/A	1958
Dr. Hans-Peter Gerber Ph.D.	Chief Scientific Officer	535,66k	N/A	1963
Ms. Jane Chung R.Ph.	President & COO	869,43k	N/A	1971
Dr. James R. Swartz DSc, Ph.D., Sc.D.	Founder	N/A	N/A	N/A
Mr. Edward C. Albini M.B.A	CFO & Secretary	554,79k	N/A	1958
Dr. Venkatesh Srinivasan Ph.d.	Chief Technical Operations Officer	N/A	N/A	1962
Mr. David Pauling J.D., M.A.	General Counsel	N/A	N/A	N/A
Ms. Linda A. Fitzpatrick	Chief People & Communications Officer	554,22k	N/A	1957
Dr. Nicki Vasquez Ph.D.	Chief Portfolio Strategy & Alliance Officer	N/A	N/A	1963
Ms. Regina Cheng	Vice President & Controller	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Corporate Governance

Sutro Biopharma, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 7. Die grundlegenden Scores sind Audit: 4, Vorstand: 6, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.